Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO ...

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment Glutamine silences BATF2 and leads to a weakened immune response ...

Recent findings reveal Cornell prime dots can activate the immune system against melanoma, improving cancer immunotherapy ...

Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...